Esperion Therapeutics, Inc.

NASDAQ:ESPR

Biotechnology

Healthcare
$3.18 -0.32%

+$0.00 today

Market cap
$661.15M
Beta
1.07
P/E (TTM)
-107.3
EPS (TTM)
-$0.03
52W Low $0.95High $4.18

Volume 0.00M

Average 12.29M

ESPR Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Esperion Therapeutics, Inc.NASDAQ: ESPR

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows in line with its trailing trend

Q1 FY2026 selling, general & admin of $43.12M rose 0.3% year over year, behind the +1.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 4.1% from the prior quarter. Over 3 fiscal years it compounded at +15.0% a year.

Context

  • Selling, general & admin amounted to 41.1% of revenue in FY2025, down 7.9 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 1 analysts of $459.75M (+177.3%) for the fiscal year ending Dec 2026, a step up from the +1.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$43.12M+4.1% QoQ
Last fiscal yearDec 2025
$165.79M+1.7% YoY
LTMMar 2026
$165.91M+1.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.3%+177.6%+177.3 pp
1 year+1.7%+177.3%+175.7 pp
3-year CAGR+15.0%+58.2%+43.2 pp
5-year CAGR+51.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
165.79M USD
Year-over-year change
+1.7%
4-year CAGR
-2.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ESPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1.1% is the 8th highest of 10, against a peer median of +22.5%.
  • Selling, general & admin amounts to 39.7% of revenue for ESPR, versus a peer median of 95.4%.
ESPR Competitors
Selling, General & Admin for ESPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SIGASIGA Technologies, Inc.LTM Mar 2026$4.67T USD+20374087.6%-55.3%4982813.7%
OFIXOrthofix Medical Inc.LTM Mar 2026$555.96M USD+4.1%+13.9%67.4%
SNDLSNDL Inc.LTM Mar 2026CA$210.35M CAD-3.8%+10.0%22.4%
EBSEmergent BioSolutions Inc.LTM Mar 2026$180.5M USD-32.3%-18.1%26.7%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$165.91M USD+1.1%+15.0%39.7%
RGNXREGENXBIO Inc.LTM Mar 2026$83.82M USD+6.5%-1.0%95.4%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$71.75M USD+22.5%+14.7%142.7%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$25.39M USD+44.8%-5.3%—
ABSIAbsci CorporationLTM Mar 2026$17.68M USD+91.0%—962.7%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$10.49M USD+24.0%+4.5%—
Peer median (excluding ESPR) —+22.5%+1.8%95.4%

Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.45M75.48M116.33M332.31M403.14M
Cost of Revenue14.22M26.97M43.27M68.6M129.22M
Gross Profit64.23M48.51M73.07M263.71M273.91M
Gross Margin81.9%64.3%62.8%79.4%67.9%
Research & Development105.98M118.93M86.11M46.24M47.85M
Selling, General & Admin184.99M109.08M142.52M163.07M165.79M
Operating Expenses290.96M228.01M228.63M209.31M213.64M
Depreciation & Amortization612K500K164K63K105K
EBITDA(222.14M)(176.35M)(150.11M)7.57M63.87M
EBITDA Margin-283.2%-233.7%-129.0%2.3%15.8%
Operating Income(226.73M)(179.5M)(155.56M)54.4M60.27M
Operating Margin-289.0%-237.8%-133.7%16.4%15.0%
Interest Income00003.5M
Interest Expense46.35M56.81M58.98M59.25M84.6M
Other Income / Expenses(42.38M)(54.16M)(53.69M)(106.15M)(81.11M)
Income Before Tax(269.11M)(233.66M)(209.25M)(51.75M)(20.84M)
Pre-Tax Margin-343.0%-309.6%-179.9%-15.6%-5.2%
Income Tax Expense00001.84M
Net Income(269.11M)(233.66M)(209.25M)(51.75M)(22.68M)
Net Margin-343.0%-309.6%-179.9%-15.6%-5.6%
EPS (Basic)(11.03)(4.33)(2.03)(0.28)(0.11)
EPS (Diluted)(11.03)(4.33)(2.03)(0.28)(0.11)
Weighted Avg Shares28.9M66.41M103.11M187.18M207.87M
Weighted Avg Shares (Diluted)28.9M66.41M103.11M187.18M207.87M

Esperion Therapeutics, Inc.

NASDAQ:ESPR

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.